HC Wainwright Lowers Earnings Estimates for Tyra Biosciences

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Analysts at HC Wainwright cut their Q2 2026 EPS estimates for shares of Tyra Biosciences in a research report issued on Thursday, May 14th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.69) per share for the quarter, down from their prior forecast of ($0.65). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.74) EPS, Q1 2027 earnings at ($0.74) EPS, Q2 2027 earnings at ($0.77) EPS and FY2027 earnings at ($3.09) EPS.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.04).

Other equities analysts have also recently issued reports about the stock. Canaccord Genuity Group assumed coverage on shares of Tyra Biosciences in a research note on Monday, April 6th. They set a “buy” rating and a $50.00 price target on the stock. Wall Street Zen downgraded shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 24th. Cantor Fitzgerald initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, February 24th. They set an “overweight” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Monday, April 20th. Finally, Barclays initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, January 27th. They set an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.

Tyra Biosciences Stock Performance

Shares of TYRA opened at $35.66 on Tuesday. The stock has a market capitalization of $2.12 billion, a P/E ratio of -16.36 and a beta of 0.79. The company’s fifty day moving average is $36.19 and its two-hundred day moving average is $29.23. Tyra Biosciences has a 1 year low of $8.75 and a 1 year high of $40.65.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Gilla Kaplan sold 14,295 shares of the firm’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total transaction of $528,486.15. Following the completion of the sale, the director owned 28,231 shares of the company’s stock, valued at approximately $1,043,700.07. This trade represents a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 12.50% of the company’s stock.

Institutional Trading of Tyra Biosciences

Hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. grew its position in shares of Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after buying an additional 1,841 shares in the last quarter. Hilton Head Capital Partners LLC acquired a new position in Tyra Biosciences in the first quarter worth $30,000. Caitong International Asset Management Co. Ltd acquired a new position in Tyra Biosciences in the fourth quarter worth $51,000. Chung Wu Investment Group LLC acquired a new position in Tyra Biosciences in the fourth quarter worth $53,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Tyra Biosciences by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock worth $68,000 after purchasing an additional 534 shares during the period. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.